References
- Manilos N, Schreiber L. Current concepts in the etiopathogenesis and treatment of systemic lupus erythematosus. Aust NZ Med 1986; 16: 729–43
- Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner H P. High-dose intravenous idiopathic thrombocytopenic purpura in childhood. Lancet June, 1981; 1228–31
- Imbach P, Barundun S, Baumgartner C, Hirt A, Hofer F, Wagner H P. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediat Acta 1981; 46: 81–86
- Gaedicke G, Teller W M, Kohne E, Dopfer R, Niethammer D. IgG therapy in systemic lupus erythematosus. Two case reports. Blut 1984; 48: 387–90
- Corvetta A, Delia R, Romagnoletti F, Panico F, Gabrielli A. High-dose intravenous immunoglobulin therapy in patients with lupus encephalitis: report of two cases. Clin Exp Rheum 1987; 5/5: 2, 208 Posters
- Sugisaki T, Shiwachi S, Yonekura M, Kitazawa K, Yamamoto J, Uchida J, Saito K, Shibata T, Kawasumi H, Takase T, Soeda K. High-dose intravenous gammaglobulin for membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis. Fed Proc 1982; 41: A-1, 692
- Berkman S A, Lee M L, Gale R P. Clinical uses of intravenous immunoglobulin. Seminars in Hematology April 1988; 25(2)140–58
- Lin R Y, Racis S P. In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration. Int Arch Allergy Appl Immunol 1986; 79: 286–90
- Sato M, Kojima H, Koshikawa S. Modification of immune complexes deposited in glomeruli in tissue sections treated with sulfonized gamma-globulin. Clin Exp Immunol 1986; 64: 623–8
- Jungi T W, Santer M, Lerch P G, Barandun S. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc-receptors. Vox Sang 1986; 51: 18–26